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Abstract: Intraperitoneal (IP) therapy with platinum (Pt)-based drugs has shown promising 
results clinically; however, high locoregional concentration of the drug could lead to adverse 
side effects. In this study, IP administration was coupled with a folate receptor-targeted (FRT) 
liposomal system, in an attempt to achieve intracellular delivery of the Pt-based drug carboplatin 
in order to increase therapeutic efficacy and to minimize toxicity. In vitro and in vivo activity of 
FRT carboplatin liposomes was compared with the activity of free drug and nontargeted (NT) 
carboplatin liposomes using FR-overexpressing IGROV-1 ovarian cancer cells as the model. 
Significant reduction in cell viability was observed with FRT liposomes, which, compared with 
the free drug, provided an approximately twofold increase in carboplatin potency. The increase 
in drug potency was correlated with significantly higher cellular accumulation of Pt resulting 
from FRT liposomal delivery. Further evaluation was conducted in mice bearing intraperitoneally 
inoculated IGROV-1 ovarian tumor xenografts. A superior survival rate (five out of six animals) 
was achieved in animals treated with FRT carboplatin liposomes, injected intraperitoneally with 
a dose of 15 mg/kg and following a schedule of twice-weekly administration for 3 weeks. In 
contrast, no survivors were observed in the free drug or NT carboplatin liposome groups. The 
presence of cancer cells in lung and liver tissues was observed in the saline, free carboplatin, 
and NT carboplatin liposome groups. However, there was no sign of cancer cells or drug-
related toxicity detected in tissues from the animals treated with FRT carboplatin liposomes. 
The results of this study have demonstrated for the first time that the approach of coupling IP 
administration with FRT liposomal delivery could provide significantly improved therapeutic 
efficacy of carboplatin in the treatment of metastatic ovarian cancer.
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Introduction
Poor prognosis and fewer treatment options make advanced ovarian cancer, one of 
the leading causes of cancer-related death in women, difficult to treat.1,2 Inadequate 
drug concentration at the tumor site is the major cause of treatment failure in solid 
tumors of peritoneal origin.3,4 Drug administration through the intraperitoneal (IP) 
route could provide a number of benefits: (1) the drug is administered directly to the 
site of disease, the peritoneal cavity; (2) IP administration could achieve a higher 
locoregional drug concentration and a longer half-life of a drug in the peritoneal cav-
ity than the intravenous route; and (3) absorption from the peritoneal cavity into the 
systemic circulation could expose the extraperitoneal sites of metastasis to the admin-
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istered drug.5 The proof of concept for IP chemotherapy in 
ovarian cancer patients was established by a randomized 
phase III clinical trial (Protocol 172) from the Gynecologic 
Oncology Group, showing a superior survival benefit in 
patients with stage III ovarian cancer when treated with IP 
cisplatin followed by paclitaxel after primary surgical tumor 
debulking.6 Several other studies have also demonstrated the 
significant benefit of IP chemotherapy over the intravenous 
route in ovarian cancer patients.7,8 Based on these clinical 
studies, the US National Cancer Institute has recommended 
IP chemotherapy for the treatment of advanced-stage ovar-
ian cancer.
Platinum (Pt)- and taxane-based drugs constitute the 
first-line chemotherapy treatment in ovarian cancer and 
therefore exploration with IP chemotherapy is mostly 
attempted with these two families of drugs. While IP 
chemotherapy offers a significant survival benefit in ovar-
ian cancer patients, this method of treatment has not been 
widely adopted in the clinic; this is because of scrutiny of 
some of the clinical study designs that included a number 
of variables changed at one time, including dose, frequency, 
and route of administration, making clinical adoption 
more challenging. IP administration of chemotherapy is 
also faced with various issues. In addition to the need for 
experienced personnel and facilities for the management 
of initial side effects such as abdominal discomfort and 
neuropathy from IP cisplatin administration,9 rapid absorp-
tion of the drugs into the systemic circulation or poor 
absorption/penetration into solid tumors also compromise 
the effectiveness of the IP drug treatment.8,10,11 Therefore, 
further improvements to the IP method of drug administra-
tion are necessary.
In this study, IP drug administration is coupled with an 
ovarian cancer cell targeted liposomal system to achieve 
intracellular delivery of the Pt-based drug carboplatin, so 
as to further increase the therapeutic efficacy of localized 
  chemotherapy. Recently, a number of clinical trials have 
indicated the benefit of using IP carboplatin compared with 
IP cisplatin, because of the different toxicity profiles with 
reduced abdominal discomfort and neuropathy.12–16 Therefore, 
the targeted IP administration of carboplatin for the treat-
ment of ovarian cancer should be explored. It is established 
that over 90% of epithelial ovarian cancers demonstrate 
overexpression of folate receptor (FR), which is minimally 
expressed in normal tissues or organs.17,18 Anticancer therapy 
targeting the FR is further supported by the recent phase I 
clinical trial of farletuzumab, a humanized monoclonal anti-
body against FR-alpha that has shown promising therapeutic 
effects.18,19 Therefore, a drug delivery system such as the lipo-
somal system, with a good drug payload designed to target 
the FR, could be used as the enabling technology to deliver 
carboplatin into ovarian cancer cells. The authors developed 
a FR-targeted (FRT) liposomal formulation for carboplatin 
and compared this with the free drug and nontargeted (NT) 
liposome formulation under in vitro and in vivo settings. The 
results of this study have demonstrated for the first time that 
IP administration of carboplatin-loaded FRT liposomes could 
produce significant improvement in the therapeutic efficacy 
of carboplatin in a FR-overexpressing, IP IGROV-1 ovarian 
tumor xenograft model.
Materials and methods
Materials
Supplies of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine 
(DPPC), 1,2-distearoyl-sn-glycero-3-phosphatidylcholine 
(DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-1000] (ammonium salt) 
(DSPE-PEG1000), and 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[folate(polyethylene glycol)-2000] (ammonium 
salt) (DSPE-PEG2000-folate) were purchased from Avanti 
Polar Lipids, Inc (Alabaster, AL). Supplies of 3-(4,5-dime-
thylthiazoly-2)-2,5-diphenyltetrazolium bromide (MTT) and 
dimethyl sulfoxide were purchased from MP Biomedicals 
LLC (MP Biomedicals Asia Pacific, Singapore).   Chloroform 
was obtained from Merck and Co, Inc (Whitehouse 
  Station, NJ). Carboplatin injection was purchased from Teva 
Pharmaceuticals Industries Ltd (Petah Tikva, Israel) through 
the pharmacy of the National University Hospital, Singapore. 
Carboplatin (powdered drug), 10% buffered formalin solu-
tion, glacial acetic acid, crystal violet, Pt standard solution 
for atomic absorption spectroscopy (AAS), Sephadex® G-50, 
and all other reagents were purchased from Sigma-Aldrich 
Co, LLC (St Louis, MO).
Mice and tumor cell line
Six- to eight-week-old female CB-17 severe combined 
immunodeficiency mice were purchased from Charles River 
Laboratories International, Inc (Wilmington, MA). The ani-
mals were housed in microisolator cages in a pathogen-free 
animal bio-safety level-2 facility. Mice were maintained 
on a folate-free diet (Dyets, Inc, Bethlehem, PA) 2 weeks 
before and during the experiment. All procedures involv-
ing the use and care of mice were approved by the Insti-
tutional Animal Care and Use Committee of the National 
University of Singapore and were performed in line with 
the National Advisory Committee for Laboratory Animal 
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Research guidelines. The FR-positive human ovarian 
cancer cell line IGROV-1 was a gift from Professor Larry 
H Matherly, Wayne State University School of Medicine, 
Detroit, MI. The cell line was cultured in folate-free RPMI 
1640 media (Gibco, Grand Island, NY), supplemented 
with 100 U/mL penicillin, 100 µg/mL streptomycin, and 
10% fetal bovine serum (FBS; HyClone Laboratories, Inc, 
Logan, UT) at 37°C in a humidified atmosphere contain-
ing 5% CO2.
Liposome making and drug loading
Liposome formulations were prepared according to an 
established procedure.20 The following lipid compositions 
were used for the different liposomal formulations. For NT 
liposomes, the compositions were DPPC/DSPE-PEG1000 
or DSPC/DSPE-PEG1000 in a molar ratio of 95:5, and are 
denoted as DPPC-NT and DSPC-NT, respectively. For 
FRT liposomes, the compositions were DPPC/DSPE-
PEG1000/DSPE-PEG2000-folate or DSPC/DSPE-PEG1000/
DSPE-PEG2000-folate in a molar ratio of 95:4.8:0.2, and 
are denoted as DPPC-FRT and DSPC-FRT, respectively. 
Briefly, lipids in appropriate proportions were dissolved in 
chloroform and the mixture was subsequently dried under 
a stream of nitrogen gas to make a fluffy lipid film. The 
sample was placed under vacuum to remove residual solvent. 
The resultant lipid film was hydrated with 0.9% sodium 
chloride (pH 7.5) for 1 hour with continuous stirring, and 
it was subsequently extruded ten times using an extruder 
(Thermobarrel Extruder; Northern Lipids Inc, Vancouver, 
BC, Canada) through stacked 100 nm polycarbonate mem-
branes. Both hydration and extrusion steps were performed 
at a temperature of 55°C ± 2°C.
Carboplatin was encapsulated in liposomes according 
to the passive equilibration method.20 Briefly, the extruded 
liposome sample was added to carboplatin powder at a 
drug-to-lipid (D/L) weight ratio of 0.25:1 and incubated at 
55°C ± 2°C with gentle stirring for 1 hour. At specified time 
points, an aliquot of the drug-liposome mixture was passed 
down a 1 mL Sephadex G-50 spin column pre-equilibrated 
with 0.9% saline (pH 7.5) to separate unincorporated carbo-
platin from the liposomes, with centrifugation at 680 × g for 
3 minutes. All liposomal samples were stored at 2°C–8°C 
until required. The mean diameter (size) and polydispersity 
index of empty and drug-loaded liposomes were determined 
at 632 nm, using a Zetasizer® (3000 HS; Malvern Instruments 
Ltd, Worcestershire, UK).
To determine the final D/L weight ratio and encap-
sulation efficiency, carboplatin and liposomal lipid 
concentrations were determined. Briefly, carboplatin 
concentration was analyzed in duplicate by AAS using a 
spectrometer (PerkinElmer AAnalyst 100; PerkinElmer 
Inc, Waltham, MA) attached to a graphite tube atomizer, 
according to an established procedure.20 Samples were 
diluted with 1% nitric acid to yield a final Pt concentration 
of 50–250 ng/mL. The analysis was performed at a wave-
length of 265.9 nm, and the temperature was calibrated to 
be 90°C for 30 seconds, 120°C for 10 seconds, 1100°C 
for 15 seconds, 2700°C for 5 seconds (reading time), 
and 30°C for 40 seconds. A standard curve was plotted 
using a Pt standard solution. The Fiske and Subbarow21 
phosphate assay method was used to determine liposomal 
lipid concentrations.
Cryogenic transmission electron 
microscopy
Morphological features of empty and drug-loaded FRT 
liposomes were examined through cryogenic transmission 
electron microscopy (cryo-TEM). Briefly, diluted liposome 
samples were placed onto a copper grid (∼3.8 µL) and blotted 
to form a thin aqueous layer. Subsequently, the sample was 
flash-frozen in liquid ethane and transferred to a cryo-TEM 
grid holder precooled and maintained in liquid nitrogen. The 
cryo-TEM specimen holder was subsequently transferred to 
a transmission electron microscope (JEM-2010F; Japan Elec-
tron Optics Laboratory Co, Ltd, Tokyo, Japan) for analysis 
at a voltage of 120 kV .
In vitro drug release
The release of carboplatin from liposomes was determined 
by dialyzing 0.5 mL samples (1 mg/mL lipid concentration) 
in mini dialysis cassettes (Thermo Fisher Scientific Inc, 
Rockford, IL; molecular weight cutoff 3.5 K) against 0.5 L of 
phosphate-buffered saline (PBS, pH 7.4) at 37°C for 72 hours 
with constant stirring. Separate dialysis cassettes were used 
for each time point. For release in serum-containing medium, 
drug-loaded liposomes were mixed with an equal volume of 
FBS and incubated at 37°C over 48 hours. At specified time 
points, aliquots of the mixture were taken and passed down a 
1 mL Sephadex G-50 spin column. Carboplatin and   liposomal 
lipid concentrations were subsequently determined as previ-
ously described.
Cellular accumulation of liposomal 
carboplatin
Fluorescent liposomes were prepared for the study of the 
cellular accumulation of liposomal carboplatin. Both NT 
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and FRT liposomes were labeled with 0.5 mol% DiI, and all 
the steps were carried out either in the dark or by wrapping 
the samples in aluminum foil. IGROV-1 cells (1 × 106) were 
plated in 35 mm dishes and allowed to attach overnight. After 
24 hours, 250 µM of free carboplatin or carboplatin-loaded 
NT or FRT liposomes was added to the cells and they were 
incubated for 24 hours at 37°C. At the end of the incubation 
period, the cells were washed three times with cold PBS to 
remove the unbound liposomes, and they were visualized 
under fluorescent microscopy (Nikon ECLIPSE TE2000-U; 
Nikon Instruments Inc, Melville, NY). Images were captured 
using a Digital Eclipse DXM1200 digital camera (Nikon 
Instruments Inc). For the determination of intracellular Pt 
content, cells were scraped off the dish after 16 hours of 
treatment with various forms of carboplatin and were pelleted 
at 1200 rpm for 3 minutes. The cells were washed at least 
twice with PBS before performing a cell count with trypan 
blue. Subsequently, 1 × 105 cells were digested in 50 µL 
of concentrated nitric acid by heating at 85°C for 1 hour. 
Cell debris was removed by centrifugation at 13,000 rpm 
for 15 minutes. The resultant sample was then diluted four 
times with double-distilled water before the determination 
of Pt content by AAS.
In vitro cytotoxicity assay
Approximately 5000 cells per well were seeded in 96-well 
plates and allowed to attach overnight. On the follow-
ing day, 200 µL of fresh medium alone or containing the 
required concentrations of carboplatin in free or liposome 
forms was added to the cells. The plates were subsequently 
incubated at 37°C for 72 hours. At the end of this incuba-
tion period, 50 µL of MTT in media (1 mg/mL) was added 
to the cells and they were incubated for a further 4 hours. 
Finally, the precipitated formazan was solubilized in 150 µL 
of dimethyl sulfoxide, and absorbance was read at 570 nm 
using a plate reader (Tecan Infinite® M2000; Tecan Group 
Ltd, Mannedorf, Switzerland). Cancer cell viability was 
calculated from the absorbance values based on the follow-
ing equation:
  Viability
AbsA bs
AbsA bs
100%,
test blank
controlb lank
=
−
−
×
where Abstest, Absblank, and Abscontrol represent the absor-
bance  readings  from  the  drug-treated  cells,  wells 
without cells (media alone), and the untreated cells, 
respectively. The IC50 values were estimated from the MTT 
viability data using CalcuSyn software (v 3.0; Biosoft, 
Cambridge, UK).
In vivo efficacy study
Twenty-four female severe combined immunodeficiency 
mice were inoculated intraperitoneally with 5 × 106 
IGROV-1 cells.22 After 14 days of tumor inoculation, the 
mice were randomly divided into four groups (six per 
group) and injected intraperitoneally with (1) saline, (2) 
free carboplatin, (3) carboplatin-loaded NT liposomes, 
or (4) carboplatin-loaded FRT liposomes. Carboplatin was 
administered at a dose of 15 mg/kg and following a schedule 
of twice-weekly administration (on Monday and Thursday) 
for a total of 3 weeks (ie, on days 14, 18, 21, 25, 28, and 32). 
Body weight of the mice was monitored at least three times a 
week from the date of arrival of the animals until the start of 
experiment, and then daily during treatment with carboplatin; 
this was in accordance with Institutional Animal Care and 
Use Committee-approved protocol. All mice were monitored 
daily for signs of decrease in physical activity, pain, and 
disease progression. Severely ill animals or animals showing 
weight loss or gain in excess of 20% were euthanized with an 
overdose of inhaled carbon dioxide. Mice surviving till the 
end of the experiment were termed long-term survivors and 
were euthanized on day 60.
All mice undergoing efficacy study were subjected to 
blood collection 24 hours after doses 2, 4, and 6. Briefly, 
50 µL of blood was collected from each mouse in heparin-
containing tubes by facial vein bleeding technique. This 
nonterminal procedure allows repeated sampling using 
alternate sides of the face (at the area of the mandible). 
The blood sample contains a mixture of venous and arterial 
blood. Plasma was obtained by centrifugation at 13,000 rpm 
for 15 minutes and was stored at −80°C until analysis. 
Plasma Pt content was determined by AAS according to an 
established procedure.23 The plasma samples were mixed 
with concentrated nitric acid and heated at 85°C for 1 hour. 
Debris was pelleted by centrifugation at 13,000 rpm for 
15 minutes, and the resultant supernatant was diluted with 
double-distilled water for AAS analysis, as previously 
described.
histopathological evaluation of tissue 
sections
Lungs, liver, and kidneys were excised from all groups 
of mice undergoing chemotherapy for histopathological 
evaluation of the tissue samples. The tissues were fixed in 
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10% buffered formalin solution, embedded in paraffin, and 
subsequently sectioned at 4 µm for hematoxylin and eosin 
staining. Tissues from at least three mice per group were 
stained and analyzed by a board-certified veterinary patholo-
gist blinded to the study.
Statistics
Unless specified otherwise, results are expressed as the 
mean plus or minus the standard error of the mean from 
three independent experiments. Statistical analyses were 
performed with one-way analysis of variance and the post hoc 
Newman–Keuls test using GraphPad Prism® software (v 2.00; 
GraphPad Software Inc, San Diego, CA). Survival curves 
were estimated using the Kaplan–Meier technique through 
MedCalc® statistical software (v 11.4.4.0; MedCalc Software, 
Mariakerke, Belgium). A log-rank test for comparisons was 
used when required. A P-value of ,0.05 was considered to 
be statistically significant.
Results
Carboplatin encapsulation  
into NT and FRT liposomes
As the first step, encapsulation of carboplatin into   liposomes 
was optimized based on the bulk lipid component. Two 
saturated lipids, DPPC and DSPC, were chosen, as the 
use of these lipids would yield gel-phase lipid bilayers 
at physiological temperatures that promote stable drug 
  encapsulation. Carboplatin was encapsulated into the lipo-
somes using the passive equilibration method described by 
Woo et al.20 The initial D/L weight ratio used for carboplatin 
encapsulation was 0.25:1, and the liposomal lipid concen-
tration was 80 mg/mL with a drug-loading temperature 
of 55°C. As demonstrated in Figure 1A, encapsulation of 
carboplatin occurred within 15 minutes of incubation, and 
maximum loading was achieved at 60 minutes for the dif-
ferent formulations. The final D/L weight ratios achieved 
in the DPPC-NT and the DSPC-NT liposomes were 
0.062 ± 0.004 and 0.040 ± 0.006, respectively. Similar drug 
loading was achieved in DPPC-FRT and DSPC-FRT, with 
final D/L weight ratios of 0.057 ± 0.006 and 0.036 ± 0.003, 
respectively. To examine how efficient the drug encapsu-
lation procedure was, drug encapsulation efficiencies for 
DPPC-NT, DPPC-FRT, DSPC-NT, and DSPC-FRT lipo-
somes were calculated and found to be 25%, 23%, 16%, 
and 14%, respectively. DPPC-based liposomes appeared to 
have slightly higher drug encapsulation than DSPC-based 
liposomes, although the difference was not statistically 
significant (P . 0.05).
The mean size of all liposome formulations, regard-
less of carboplatin encapsulation, was in the range of 
100–110 nm, with polydispersity indices of ,0.15, as 
determined by the Zetasizer. Cryo-TEM was performed 
to further characterize the morphology of empty and 
carboplatin-loaded DPPC-FRT liposomes (Figure 1B). As 
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Figure 1 (A) Time course of carboplatin loading by passive equilibration method 
into  different  liposomes;  (B)  representative  cryogenic  transmission  electron 
microscopy images of empty and carboplatin-loaded liposomes* from at least three 
liposome batches.
Notes: Results shown are the mean plus or minus the standard error of the mean 
obtained from at least three independent experiments; ♦ = DPPC/DSPE-PEG1000 [molar 
ratio, 95:5], or DPPC-NT); *■ = DPPC/DSPE-PEG1000/DSPE-PEG2000-folate [molar ratio, 
95:4.8:0.2], or DPPC-FRT); ▲ = DSPC/DSPE-PEG1000 [molar ratio, 95:5], or DSPC-NT); 
● = DSPC/DSPE-PEG1000/DSPE-PEG2000-folate (molar ratio, 95:4.8:0.2; DSPC-FRT).
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carboplatin is a Pt-based drug with high electron density,20 
substantial difference in the   cryo-TEM images between 
empty and drug-loaded liposomes was anticipated. Indeed, 
carboplatin-loaded liposome showed a dense core, which 
was absent in empty liposome. Carboplatin is likely to be 
precipitated after loading into liposomes, with the sample 
cooled to room temperature. This is supported by calculating 
the concentration of liposome-associated carboplatin, which 
was found to be 45 mg/mL based on the final D/L weight 
ratio of 0.057:1, a trap volume of 1 µL/µmol lipid for the 
100 nm DPPC-FRT liposome, and the water solubility of 
carboplatin of 14 mg/mL.20
In vitro drug release  
from NT and FRT liposomes
The in vitro drug release profiles were obtained for DPPC-NT, 
DPPC-FRT, DSPC-NT, and DSPC-FRT liposomes, based on 
the dialysis method against a sink of 1:1000 v/v PBS at 37°C 
(Figure 2A). All drug release profiles were similar, and they 
did not indicate any significant difference between the NT 
and FRT formulations at different time points (P . 0.05). 
A similar study was performed in the presence of 50% 
FBS at 37°C (Figure 2B), and the results showed a similar 
trend – no statistical significant difference was seen when 
comparing NT and FRT liposomes. However, carboplatin 
was released faster from the liposomes in serum-containing 
medium than PBS alone.
Since DPPC-based liposomes (DPPC-FRT and DPPC-
NT) showed higher drug encapsulation than DSPC-based 
liposomes, and since they did not show any significant 
difference in drug release pattern, all further studies were 
performed with DPPC-FRT and DPPC-NT liposomes. 
Henceforth, DPPC-NT and DPPC-FRT liposomes will 
be termed NT and FRT liposomes, respectively, unless 
otherwise specified.
Intracellular accumulation of carboplatin 
in free and liposomal forms
For an anticancer drug such as carboplatin to exert its 
biological activity, it is crucial for the drug to be delivered 
intracellularly. As such, the next set of experiments in the 
current study aimed to probe the intracellular accumulation 
of carboplatin in free and liposomal forms. The accumulation 
of the NT and FRT liposomes was first probed in the FR-
overexpressing IGROV-1 ovarian cancer cell line, whereby 
the liposomes were tagged with the fluorescent lipid DiI. FRT 
liposomes (Figure 3A, panel i) showed much higher cellular 
accumulation than NT liposomes (Figure 3A, panel ii), and 
in the presence of 1 mM of free folic acid, the accumulation 
of the FRT liposomes was completely blocked (Figure 3A, 
panel iii). Furthermore, Pt concentration in IGROV-1 cancer 
cells was determined and compared among the three formula-
tions of carboplatin. As shown in Figure 3B, the intracellular 
Pt level in IGROV-1 cells treated with FRT liposomes was 
approximately twofold higher than those treated with free 
carboplatin or NT carboplatin liposomes, which was statisti-
cally significant (P , 0.05).
Viability of ovarian cancer cells  
upon exposure to carboplatin  
in free or liposomal forms
Figure 4 illustrates the concentration-dependent reduction 
in IGROV-1 cell viability upon exposure to carboplatin 
as free drug or as delivered via NT and FRT liposomes. 
80
80
A
B
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
C
u
m
u
l
a
t
i
v
e
 
d
r
u
g
 
r
e
l
e
a
s
e
 
(
%
)
60
60
40
Time (hours)
40
20
20
0
60 40
Time (hours)
20 0
0
80
60
40
20
0
Figure 2 Cumulative release of carboplatin from various liposomes at 37°C under 
sink conditions (1:1000 v/v) in (A) phosphate-buffered saline and (B) 50% (v/v) fetal 
bovine serum.
Notes: Results shown are the mean plus or minus the standard error of the mean 
obtained from at least three independent experiments;  = DPPC/DSPE-PEG1000 [molar 
ratio, 95:5], or DPPC-NT);  = DPPC/DSPE-PEG1000/DSPE-PEG2000-folate [molar ratio, 
95:4.8:0.2], or DPPC-FRT); ▲ = DSPC/DSPE-PEG1000 [molar ratio, 95:5], or DSPC-NT); 
 = DSPC/DSPE-PEG1000/DSPE-PEG2000-folate (molar ratio, 95:4.8:0.2; DSPC-FRT).
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Cell viability was also examined in cells treated with FRT 
carboplatin liposomes in the presence of 1 mM of free folic 
acid. Based on the cell viability data, the IC50 values for free 
carboplatin, NT carboplatin liposomes, and FRT carboplatin 
liposomes were estimated and found to be 24.0 ± 1.6 µM, 
40.1 ± 5.0 µM, and 13.1 ± 0.6 µM, respectively, with FRT 
liposomes significantly more effective in reducing cell 
viability (Table 1). When 1 mM of free folic acid was added 
to the FRT carboplatin treatment, the IC50 value was signifi-
cantly increased – from 13.1 ± 0.6 µM to 29.0 ± 5.3 µM. 
Of note, drug-free NT liposomes and FRT liposomes did 
not show any cytotoxicity towards IGROV-1 cells, with 
viability of 98.9% ± 3.4% and 99.1% ± 0.3%, respectively, 
at the highest liposomal lipid concentration of 500 µM. This 
  finding is in agreement with a previous report that empty FRT 
liposomes were nontoxic to the animals and did not con-
tribute to the anticancer activity.24 Collectively, the   current 
study’s in vitro results are in agreement with the notion that 
  FR-mediated endocytosis of FRT liposome-encapsulated 
drug could enhance the intracellular accumulation as well as 
the potency of the encapsulated drug.
Free carboplatin NT liposomes FRT liposomes
0
100
200
300
400
p
p
b
 
P
t
 
p
e
r
 
1
0
5
 
c
e
l
l
s
B
A
*P < 0.05
*P < 0.05
Figure 3 (A) Cellular accumulation of DiI-labeled folate receptor-targeted (FRT) 
liposomes (i), nontargeted (NT) liposomes (ii), and FRT liposomes in the presence 
of 1 mM of free folic acid (iii) in IGROV-1 cells after 24 hours. (B) Cellular platinum 
(Pt) content in IGROV-1 cells after treatment with free carboplatin, carboplatin-
loaded NT liposomes, or carboplatin-loaded FRT liposomes.
Notes:  Images  are  representative  of  three  independent  experiments;  data 
represent the mean plus or minus the standard error of the mean obtained from 
three independent experiments.
Abbreviation: ppb, parts per billion.
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carboplatin-loaded nontargeted liposome (), carboplatin-loaded folate receptor-
targeted liposome (), and carboplatin-loaded folate receptor-targeted liposome 
with 1 mM folic acid ().
Note: Data represent the mean plus or minus the standard error of the mean 
obtained from five independent experiments.
Table  1  IC50  values  of  free  carboplatin,  carboplatin-loaded 
nontargeted  (NT)  liposomes,  and  carboplatin-loaded  folate 
receptor-targeted (FRT) carboplatin liposomes in IGROV-1 cells
Group IC50 (µM)a
Free drug 24.0 ± 1.6b,c
Carboplatin-loaded NT liposomes 40.1 ± 5.0b,c
Carboplatin-loaded FRT liposomes 13.1 ± 0.6c,d
Carboplatin-loaded FRT liposomes + 1 mM free folic acid 29.0 ± 5.3d
Notes: aResults shown are the mean plus or minus the standard error of the mean 
obtained from at least three independent experiments; bP , 0.05, free drug versus 
NT  liposomes;  cP  ,  0.05,  FRT  liposomes  versus  free  drug  and  NT  liposomes; 
dP , 0.05, FRT liposomes with versus without 1 mM free folic acid.
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In vivo therapeutic efficacy of carboplatin 
in free and liposomal forms
The therapeutic efficacy of carboplatin delivered in free or 
liposomal forms was investigated in the intraperitoneally 
grown human IGROV-1 ovarian tumor xenograft model, 
which was selected to mimic the clinical nature of tumor 
burden in women with advanced-stage ovarian cancer and 
FR overexpression.22 Carboplatin was given at 15 mg/kg 
and following a schedule of two doses per week (on Monday 
and Thursday) for a total of 3 weeks. Kaplan–Meier survival 
curves are presented in Figure 5A, and the survival data 
are summarized in Table 2. Mice in the saline control, free 
  carboplatin, and NT carboplatin liposome groups did not 
have any survivors at the end of the study period (60 days 
post-tumor inoculation), and all died within 19–39 days post-
tumor inoculation. All dead mice were autopsied to confirm 
that they had died from tumor burden. The median survival 
time for the saline control, free drug, and NT carboplatin 
liposome groups was 26.5, 26, and 28.5 days, respectively. 
In contrast, five out of six mice treated with FRT carbo-
platin liposomes survived until the end of the study, with a 
survival rate of 83%. A log-rank test indicated a statistically 
significant difference between the FRT carboplatin liposome 
group and the saline control, free drug, and NT carboplatin 
liposome groups (P , 0.01).
Previous studies have shown that IP administration of 
doxorubicin encapsulated in FRT and NT liposomes led to 
a longer circulation lifetime than free doxorubicin.24 In light 
of this finding, plasma Pt concentration in the current study 
was determined each week during the 3-week treatment 
period to estimate the level of carboplatin in the systemic 
circulation. Plasma samples were collected 24 hours after 
doses 2, 4, and 6. As shown in Figure 5B, the plasma Pt 
concentration of the free drug group was approximately 
twofold lower than the concentrations of the NT and FRT 
carboplatin liposome groups during the first and second 
weeks of treatment, although the difference was not statisti-
cally significant (P . 0.05).
Changes in body weight of the animals were monitored 
over the study period of 60 days as a gross indicator to the 
well-being of the animals under the experimental condi-
tions (Supplementary figure 1). Acute weight loss could not 
be observed in any of the treated groups during the course 
of study. However, the percent weight change at nadir for 
the NT carboplatin liposome group was found to be ∼20%, 
although the difference between this and the other groups 
was not statistically significant (Table 2). The saline control 
group demonstrated an increase in body weight, which could 
have been due to the growing tumor and the accumulation of 
ascitic fluid. Of note, the FRT carboplatin liposome group 
did not show any significant change in body weight over the 
60-day study period (P . 0.05), which is a similar result to 
that observed in the normal, healthy mice (without tumor 
or drug treatment). Future animal toxicological studies are 
necessary to fully elucidate the toxicity profile of the FRT 
carboplatin liposome formulation, involving the evaluation of 
blood chemistry (such as alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, bilirubin, creatinine, 
urea, and major electrolytes) and histological evaluation of 
vital organs (liver, gallbladder, spleen, lung, kidney, heart, 
Doses 1−2
(week 1)
0.0
P
l
a
s
m
a
 
d
r
u
g
 
c
o
n
c
 
(
m
g
/
L
) 3.0
2.0
1.0
Doses 5−6
(week 3)
Doses 3−4
(week 2)
FRT NT Free
B
A
Days post-tumor inoculation
0
S
u
r
v
i
v
a
l
 
(
%
)
20
40
60
80
100
10 30 60 50 40 20
Figure 5 (A) Kaplan–Meier survival curves of mice bearing intraperitoneal IGROV-1 
ovarian  tumor  xenograft  treated  with  saline  (blue),  free  carboplatin  (green), 
carboplatin-loaded  nontargeted  (NT)  liposomes  (red)  and  carboplatin-loaded 
folate  receptor-targeted  (FRT)  liposomes  (black).  Each  study  group  comprised 
six animals. (B) Plasma drug concentrations (conc) in animals treated with various 
intraperitoneal carboplatin formulations at a dose of 15 mg/kg. Carboplatin was 
administered for a total of six doses, and plasma samples were collected 24 hours 
after doses 2, 4, and 6.
Notes: Results shown in panel (B) were obtained from at least three mice. The 
exception to this was dose 6, with n = 2 and n = 1 for free drug and carboplatin-
loaded NT liposome groups, respectively.
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intestine, lymph nodes, marrow, bladder, and brain) under 
acute and chronic settings.
histopathological evaluation on tissues 
from treated animals
In addition to monitoring the survival of the animals, 
histopathological evaluation of tissues collected from 
the control animals and from those treated with various 
forms of carboplatin was performed to probe the presence 
of tumor cells, so as to reflect disease progression and 
therapeutic efficacy. It has been established that ovarian 
cancer cells can invade major organs such as the lungs and 
liver through the lymphatic system.1 This phenomenon 
could be seen in the IGROV-1 IP tumor xenograft model, 
whereby tumor cells were present in the lungs and livers of 
saline-treated tumor-bearing animals (Figure 6, A panels), 
with the mediastinal lymph node filled with tumor cells 
(Supplementary figure 2).
As shown in Figure 6, substantial metastasis of the tumor 
cells could be observed in the lungs obtained from the free 
carboplatin and NT carboplatin liposome groups. Tumor cells 
were found within the capillaries of the lungs as well as the 
lung lobes. In contrast, metastasis could not be observed in the 
long-term survivors treated with FRT carboplatin   liposomes. 
A similar trend was observed in the liver sections from the 
treated animals, whereby clusters of tumor cells were present 
on the outer surface of the liver capsule in the saline control, 
free carboplatin, and NT carboplatin liposome groups but not 
in the FRT carboplatin liposome group. These results suggest 
that the FRT carboplatin liposome formulation was effective 
in treating advanced metastatic ovarian cancer.
Discussion
Recent clinical trials have shed light on the usefulness of IP 
administration of Pt-based compounds to extend the overall 
survival of ovarian cancer patients.7,8,25 As mentioned, IP 
Pt-based therapy provides high locoregional concentrations 
of the drug and longer exposure in the peritoneal cavity as 
compared with the intravenous route.5 Yet, the high local 
drug concentration would potentially give rise to higher risk 
of toxicities.5 In the current study, the authors have further 
improved the approach of the IP carboplatin regimen by cou-
pling this route of drug administration with a FRT liposomal 
system as the enabling technology for achieving intracellular 
delivery of carboplatin into the ovarian cancer cells, increas-
ing the therapeutic efficacy. The in vitro and in vivo data 
demonstrated significant improvement in the therapeutic 
efficacy of carboplatin through the use of FRT liposomes in 
a metastatic FR-positive ovarian tumor xenograft model. The 
biological performance of the FRT carboplatin liposomes will 
be discussed in light of the formulation attributes.
With farletuzumab, the anti-FR monoclonal antibody, 
emerging as a promising targeted therapy for ovarian 
cancer,18,19 the development of therapies targeting the human 
FR would continue to attract much attention. Over the years, 
various research groups have developed FRT liposomes 
for different conventional chemotherapeutics, with the aim 
of increasing the therapeutic efficacy of the encapsulated 
drug.26,27 Nevertheless, limited studies are available for the 
evaluation of FRT liposome-based anticancer drug therapies 
in FR-overexpressing ovarian cancer cells/models. In view 
of the therapeutic promise of IP Pt-based drug administra-
tion and the emerging importance of FRT therapy in the 
treatment of ovarian cancer, the authors’ approach of IP 
administration of FRT carboplatin liposome formulation is 
the first to demonstrate the feasibility of such a therapeutic 
strategy that is closely in line with the anatomical disease 
site and clinically relevant.
Various factors could contribute to the superior therapeutic 
efficacy of FRT carboplatin liposomes, and the in vitro and 
in vivo data argue in favor of increased intracellular delivery 
of carboplatin through a FRT liposomal system. As evidenced 
by Figures 3 and 4, FRT liposomes could significantly 
increase the accumulation of carboplatin and thus its potency 
Table 2 In vivo efficacy of intraperitoneal administration of carboplatin in various forms in intraperitoneal IGROV-1 ovarian tumor 
xenograft
Study group Median survival  
time (days)a
Survival time 
(range in days)
Long-term  
survivorb
Weight change   
at nadir (%)c
Saline control 26.5 19–33 0/6  + 4.1 ± 1.6
Free drug 26 21–39 0/6  − 9.3 ± 7.6
NT liposomes 28.5 15–36 0/6 −20.5 ± 10.4
FRT liposomes NA 43 to .60 5/6  − 8.0 ± 1.4
Notes: aP , 0.01 by log-rank test; blong-term survivor is defined as an animal surviving until the end of the experiment (duration 60 days post-tumor inoculation); cweight 
change at nadir (%) = (weight at nadir − weight before treatment)/weight before treatment × 100%.
Abbreviations: FRT, folate receptor-targeted; NA, not applicable; NT, nontargeted.
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Figure 6 histopathological evaluation of excised lung tissue (top) and liver tissue (bottom) indicating the presence of cancer cells in mice treated with (A) saline, (B) free 
carboplatin, and (C) carboplatin-loaded nontargeted liposome. Mice treated with carboplatin-loaded folate receptor-targeted liposome (D) that survived the study period 
did not show any presence of cancer cells. 
Notes: Representative images are shown from at least three animals, with arrows indicating the presence of cancer cells.
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in the IGROV-1 ovarian cancer cells. An earlier study that 
  demonstrated enhanced accumulation of fluorescent FRT lipo-
somes (non-drug loaded), as compared with NT liposomes, 
in IGROV-1 cells and tumor-associated macrophages from 
mice bearing IP IGROV-1 tumor xenograft provides further 
evidence to support the efficacy findings of the current study.22 
Of importance, it is unlikely that the difference in the in vivo 
therapeutic outcome between the NT and FRT liposome for-
mulations could be attributed to the drug release properties 
of these two formulations, as both NT and FRT liposomes 
have similar drug release profiles (Figure 2).
The IP IGROV-1 ovarian tumor xenograft model was 
chosen to mimic the metastatic stage of ovarian cancer, 
and IP therapy will allow systemic drug exposure in the 
  extraperitoneal tumor sites after drug absorption.   Comparing 
the plasma carboplatin concentrations of the three forms 
of carboplatin during the course of the efficacy study, sys-
temic carboplatin exposure was not significantly different 
among the three formulations, albeit NT and FRT liposomes 
yielded an approximately twofold higher Pt concentration 
in plasma (Figure 5B). Thus, increased systemic exposure 
to carboplatin via FRT liposome delivery is not likely to be 
a contributing factor to the increased therapeutic activity of 
this formulation. Suboptimal cellular accumulation of car-
boplatin with NT liposomes and free carboplatin is likely to 
have resulted in poor suppression of primary tumor growth 
and metastasis.
The FRT carboplatin liposomes were administered at a 
cumulative drug dose of 90 mg/kg, which was twofold lower 
than the cumulative maximum tolerated dose of carboplatin 
in mice (reported to be 180 mg/kg for the IP route).28 Other 
studies have used lower IP doses of carboplatin in the free or 
liposomal form, at a single dose of 75–85 mg/kg,29,30 which 
could still give rise to significantly high toxicity in the case 
of NT liposomal carboplatin.29 However, the FRT carboplatin 
liposomes have yielded significant improvement in   therapeutic 
activity compared with free drug and NT liposomes.
Conclusion
The results of this study demonstrate the potential of FRT 
carboplatin liposomes to be administered to patients at a 
lower dose while maintaining therapeutic efficacy with 
reduced risk of regimen-related toxicities. Future studies 
involving optimizing the dose and frequency of the FRT 
carboplatin liposomes, together with full animal toxicologi-
cal evaluation, could facilitate the identification of a regimen 
that yields maximal therapeutic efficacy without drug-related 
toxicities.
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Figure S1 Changes in body weight in various study groups, including saline (), free 
carboplatin (), carboplatin-loaded nontargeted liposome (▲ ), carboplatin-loaded 
folate receptor-targeted liposme (), and healthy control mice ().
Notes: Body weights were measured at least three times a week, with the arrows 
indicating the intraperitoneal administration of treatment. Results shown are the mean 
plus or minus the standard error of the mean obtained from at least three mice.
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Figure S2 histopathological evaluation indicating the presence of cancer cells in 
mediastinal lymph node of saline control. 
Notes: Arrow indicates the presence of cancer cells. Representative image of lymph 
node metastasis is presented.
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